Plant-based diets cut climate impact by more than half, randomized clinical trial shows

As climate change accelerates and global temperatures continue to rise, a new randomized clinical trial provides compelling ...
YouTube on MSN

The peptide proven to reduce visceral fat (in randomized controlled trials)

Tesamorelin can selectively reduce visceral fat, as demonstrated in RCTs. But the real story is what it reveals about ...
Healio

Semaglutide reduces heavy drinking for adults with alcohol use disorder, obesity

Once-weekly semaglutide was tied to a reduction in heavy drinking days among adults with obesity and alcohol use disorder, ...
The Manila Times

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of ...
The American Journal of Managed Care

GLP-1s Reduce Heavy Drinking Days in Patients With Obesity, Alcohol Use Disorder

Compared with placebo, semaglutide achieved larger reductions in heavy-drinking days (−41.1 vs −26.4 percentage points) and ...
Medical Device and Diagnostic Industry (MD+DI)

Johnson & Johnson Launches Landmark Head-to-Head Pulsed Field Ablation Trial in Persistent Atrial Fibrillation

Johnson & Johnson has initiated the PERSIGMA randomized controlled trial (RCT), one of the first randomized studies ...
Vietnam Investment Review on MSN

Bambusa completes patient enrollment for BBT001 atopic dermatitis trial

BOSTON, April 30, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation bispecific antibodies for immunology and ...
Journal of Medical Internet Research

Effects of a Soft Robotic Exoskeleton for Gait Training on Clinical Outcomes in Patients With Parkinson Disease: Randomized Controlled Pilot Study

Effects of a Soft Robotic Exoske ...
Targeted Oncology

Phase 3 Trial of Synthetic Hypericin in CTCL Advised to Stop for Futility

A data monitoring committee recommended stopping FLASH2, a randomized double-blind placebo-controlled confirmatory phase 3 ...

Why the FDA rejected a ‘breakthrough’ melanoma drug

For patients whose skin cancer doesn’t respond to traditional treatments, a new drug called RP1 has been a lifeline—at least ...

Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis

Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation bispecific antibodies for immunology and inflammation, today announced the ...